Rates and Pattern of Antifracture Drug Use in 6475 Adults and Children With Osteogenesis Imperfecta
Main finding · AFD useResult — go to the resultStandard mean difference 0.34Authors' conclusion
These findings suggest that AFDs drugs are underutilized in the general US population of adults and children with OI. Our observed rates are lower than those reported in other studies, likely because our cohort reflects individuals in the general community rather than patients treated in specialized bone clinics.
Study context
- Population
- Adults and children with osteogenesis imperfecta (OI) in the US, MarketScan 2011–2022 and 5% Medicare sample 2006–2021; median age 21 years [IQR 8–43], 55.8% adults, 57.6% femaleplus 32,470 matched individuals
- Participants
- 6,494 adults
- Exposure
- Severe OI vs milder OI
- Outcome
- Rates and types of antifracture drug (AFD) use
Methodological detailsclaims data (MarketScan, 5% Medicare sample), matched to 5 reference patients
- Claims data (MarketScan, 5% Medicare sample)
- Matched to 5 reference patients
Main finding
AFD use
Standard mean difference
0.34
By group
As reported in the abstract
- Antifracture drugs (AFD) use in overall OI cohort
- 25.9%
Observational data: associations, not effects.
Further findings
AFD use by age and drug type
- Use highest in children, much lower in young adults, rising gradually with increasing age
- Bisphosphonates the most prescribed AFD across all age groups and OI severity levels
Original publication
Rates and Pattern of Antifracture Drug Use in 6475 Adults and Children With Osteogenesis Imperfecta. J Clin Endocrinol Metab. Published 11 September 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →